SHOULD CRYOSURGERY BE CONSIDERED A THERAPEUTIC OPTION IN LOCALIZED PROSTATE CANCER? - 11/09/11
Résumé |
In 1995, prostate cancer claimed approximately 40,000 lives in the United States and an additional 240,000 men were diagnosed with this condition.21 The optimal treatment for prostate cancer is a matter of much debate. Although there is no absolute consensus, most urologists agree that the treatment of choice for organ-confined prostate cancer (T1 and T2 tumors) occurring in young, healthy men, is radical prostatectomy. When carried out for the appropriate indication, radical surgery is associated with minimal mortality and acceptably low morbidity rates.11 , 19 , 24 Reported cure rates with surgery vary but approach 80% for low-volume disease (T1 to T2, PSA <10 ng/mL).
Cryosurgery as a treatment for localized prostate cancer has seen renewed interest in recent years because of promising initial reports citing low morbidity, minimal blood loss, short hospital stay, and high rates of negative posttreatment biopsy results.1 , 16 Use of transrectal ultrasound (TRUS) for real-time monitoring of the freezing process, improved cryoprobes, and better understanding of cryobiology have all contributed to this resurgence of interest in cryosurgical therapy.3 , 9 , 15 These advances have allowed more efficient freezing of the prostate gland while reducing damage to surrounding tissues, notably the rectum and urethral sphincter. In addition to treating organ-confined tumors, cryotherapy has been proposed as a possible low-morbidity treatment for patients with T3 disease or for patients with residual or recurrent cancer following radiation therapy.
Le texte complet de cet article est disponible en PDF.Plan
Address reprint requests to Peter R. Carroll, MD, Department of Urology, U-575, University of California, San Francisco, CA 94143–0738 |
Vol 23 - N° 4
P. 623-631 - novembre 1996 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?